[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620229":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":198,"collaborators":10,"id":200,"slug":201,"hasResults":202,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":202,"sex":208,"minAge":209,"maxAge":10,"enrollmentInfo":210,"targetDuration":213,"studyType":214,"phases":10,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":222,"whyStopped":10,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},{"fullName":5,"class":6},"Groupe français d'étude des Maladies Inflammatoires de loeil","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Multicenter cohort evaluating the safety and efficacy of upadacitinib in patients with GCA condition",null,"This is an observational, multicenter cohort evaluating the safety and efficacy of upadacitinib in patients with giant cell arteritis (GCA). Patient treatment and follow-up will be conducted in accordance with routine clinical care. No additional visits or examinations will be added for the purposes of the study. Participants will be followed as part of the usual management of their disease. No modifications will be made (no additional visits, examinations, or questionnaires). The safety and well-being of participants will therefore remain unchanged. Patients will then be followed and managed according to routine care (visits and examinations).\n\nRoutine care includes:\n\n* A clinical assessment of efficacy and safety at weeks 12, 24, 36, 52, and 104;\n* Oral prednisone treatment at the initial doses recommended by international and French guidelines, in accordance with routine care.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"David Saadoun, Professor","CONTACT","+33142178042","david.saadoun@aphp.fr",[19,36,50,62,74,88,98,112,126,140,154,162,175,187],{"facility":20,"status":10,"city":21,"state":10,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Clinique Axium - Aix-en-provence","Aix-en-Provence","13100","France","FR",{"type":26,"coordinates":27},"Point",[28,29],5.44973,43.5283,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":34,"phoneExt":10,"email":35},"Thomas SENE, MD","0442957153","dr.sene.axium@almaviva-sante.com",{"facility":37,"status":10,"city":38,"state":10,"zip":39,"country":23,"countryCode":24,"cosmosGeoPoint":40,"geoPoint":44,"contacts":45},"CHU Caen Normandie","Caen","14000",{"type":26,"coordinates":41},[42,43],-0.35912,49.18585,{"lat":43,"lon":42},[46],{"name":47,"role":15,"phone":48,"phoneExt":10,"email":49},"DE BOYSSON Hubert, MD","02 31 06 46 78","deboysson-h@chu-caen.fr",{"facility":51,"status":10,"city":52,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"CHU de Dijon","Dijon",{"type":26,"coordinates":54},[55,56],5.01391,47.31344,{"lat":56,"lon":55},[59],{"name":60,"role":15,"phone":61,"phoneExt":10,"email":10},"Samson Maxime, Pr","+33380293432",{"facility":63,"status":10,"city":64,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"CH du Mans","Le Mans",{"type":26,"coordinates":66},[67,68],0.20251,48.0021,{"lat":68,"lon":67},[71],{"name":72,"role":15,"phone":73,"phoneExt":10,"email":10},"LOZAC'H Pierre, MD","+33243432799",{"facility":75,"status":10,"city":76,"state":10,"zip":77,"country":23,"countryCode":24,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"APHM_Hôpital Nord","Marseille","13915",{"type":26,"coordinates":79},[80,81],5.38107,43.29695,{"lat":81,"lon":80},[84],{"name":85,"role":15,"phone":86,"phoneExt":10,"email":87},"Brigitte Granel, MD","0491968711","Brigitte.granel@ap-hm.fr",{"facility":89,"status":10,"city":76,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"APHM_Hôpital La Conception",{"type":26,"coordinates":91},[80,81],{"lat":81,"lon":80},[94],{"name":95,"role":15,"phone":96,"phoneExt":10,"email":97},"JARROT Pierre-André, MD","+33 4 91 38 35 22","Pierre.JARROT@ap-hm.fr",{"facility":99,"status":10,"city":100,"state":10,"zip":101,"country":23,"countryCode":24,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"GHSIF Melun","Melun","77000",{"type":26,"coordinates":103},[104,105],2.65356,48.5457,{"lat":105,"lon":104},[108],{"name":109,"role":15,"phone":110,"phoneExt":10,"email":111},"Nabil Belfeki, MD","0181741818","nabil.belfeki@ghsif.fr",{"facility":113,"status":10,"city":114,"state":10,"zip":115,"country":23,"countryCode":24,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"GHI Le Raincy Montfermeil","Montfermeil","93370",{"type":26,"coordinates":117},[118,119],2.57913,48.8982,{"lat":119,"lon":118},[122],{"name":123,"role":15,"phone":124,"phoneExt":10,"email":125},"Dellal Azeddine, MD","01. 41.70. 81.25","azeddine.dellal@ght-gpne.fr",{"facility":127,"status":10,"city":128,"state":10,"zip":129,"country":23,"countryCode":24,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"CHU Nantes - Hotel-Dieu","Nantes","44000",{"type":26,"coordinates":131},[132,133],-1.55336,47.21725,{"lat":133,"lon":132},[136],{"name":137,"role":15,"phone":138,"phoneExt":10,"email":139},"Espitia Olivier, MD","02 40 08 33 55","Olivier.espitia@chu-nantes.fr",{"facility":141,"status":10,"city":142,"state":10,"zip":143,"country":23,"countryCode":24,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"APHP_Hôpital St Antoine","Paris","75012",{"type":26,"coordinates":145},[146,147],2.3488,48.85341,{"lat":147,"lon":146},[150],{"name":151,"role":15,"phone":152,"phoneExt":10,"email":153},"Arsene Mekinian, Professor","+331 49 28 23 92","arsene.mekinian@aphp.fr",{"facility":155,"status":10,"city":142,"state":10,"zip":156,"country":23,"countryCode":24,"cosmosGeoPoint":157,"geoPoint":159,"contacts":160},"APHP_ Hôpital Pitié-Salpêtrière","75013",{"type":26,"coordinates":158},[146,147],{"lat":147,"lon":146},[161],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"facility":163,"status":10,"city":164,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"CHU Rouen_Hôpital Charles Nicolle","Rouen",{"type":26,"coordinates":166},[167,168],1.09932,49.44313,{"lat":168,"lon":167},[171],{"name":172,"role":15,"phone":173,"phoneExt":10,"email":174},"Mathilde LECLERQ, MD","0232889003.","Mathilde.Leclercq@chu-rouen.fr",{"facility":176,"status":10,"city":142,"state":177,"zip":178,"country":23,"countryCode":24,"cosmosGeoPoint":179,"geoPoint":181,"contacts":182},"APHP_Hopital Lariboisière","Île-de-France Region","75010",{"type":26,"coordinates":180},[146,147],{"lat":147,"lon":146},[183],{"name":184,"role":15,"phone":185,"phoneExt":10,"email":186},"Chloé Comarmond, Professor","+33149958127","chloe.comarmondortoli@aphp.fr",{"facility":188,"status":10,"city":142,"state":177,"zip":189,"country":23,"countryCode":24,"cosmosGeoPoint":190,"geoPoint":192,"contacts":193},"APHP_Hôpital Bichat","75018",{"type":26,"coordinates":191},[146,147],{"lat":147,"lon":146},[194],{"name":195,"role":15,"phone":196,"phoneExt":10,"email":197},"karim Sacre, Professor","+33140258316","karim.sacre@aphp.fr",{"type":199,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620229","upadacitinib-in-giant-cell-arteritis-gca-with-active-large-vessel-involvement-100620229",false,"NCT07354906","Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.","Prospective Observational Study Evaluating the Efficacy and Safety of Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.","TILT2","Inclusion Criteria:\n\nPatients aged over 18 years; Signed informed consent; Affiliation with the French national social security system; Diagnosis of newly diagnosed or relapsing GCA according to the 2022 ACR\u002FEULAR criteria; Active aortitis related to GCA demonstrated by imaging (CT angiography, MR angiography, and\u002For PET-CT); Indication for treatment with an anti-JAK agent within the scope of the marketing authorization for GCA: failure of, intolerance to, or contraindication to tocilizumab therapy; No contraindication to JAK inhibitors.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding (for women of childbearing potential, a negative serum pregnancy test will be required); History of severe immunosuppression, HIV infection, hepatitis C virus (HCV), or positive hepatitis B surface antigen (HBsAg); Non-response to or intolerance of a previous anti-JAK treatment; Positive QuantiFERON test (QFT-TB Gold In-Tube) indicating active tuberculosis (latent tuberculosis under treatment for at least 3 weeks may be included); Receipt of live vaccines within the 3 months preceding treatment initiation; History of malignancy within the past 5 years; Severe renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin\u002F1.73 m²); Hepatic dysfunction defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≥ 5 times the upper limit of normal;\n\nAbnormal blood counts:\n\nPlatelets \\\u003C 50 × 10³\u002Fmm³; Neutropenia \\\u003C 1,000\u002Fmm³; Hemoglobin \\\u003C 8 g\u002FdL; History of thromboembolic disease; History of severe cardiovascular disease.","ALL","18 Years",{"count":211,"type":212},80,"ESTIMATED","24 Months","OBSERVATIONAL","Participants will be followed as part of the usual management of their disease. No modifications will be made (no additional visits, examinations, or questionnaires). The safety and well-being of participants will therefore remain unchanged.\n\nThe participant will be informed about the study during one of their routine care visits. The information will be provided by the investigator, and the participant's non-opposition to participation in the study will be obtained.\n\nThe participant will continue to be followed as part of their usual care.\n\nData will then be collected from the participant's medical record (including medical reports, original laboratory test results, imaging reports and medical examinations, and nursing records) for the period of participation in the research, solely for the purpose of meeting the objectives of the research.\n\nThe data collected will consist of information from the patient's medical record as part of their routine follow-up and will be strictly necessary to address the primary and secondary objectives of the study. The following data will be collected: demographic data (age, sex, weight, height); clinical data (medical history, diagnosed condition, disease activity), treatments, biological data, imaging data, and adverse events. No genetic data will be collected as part of the study. There will be no transfer of data abroad, and no additional questionnaires, examinations, or visits will be added by the research.",[217],"Giant Cell Arteritis (GCA)",[219,220,221],"Giant Cell Arteritis (GCA) .","Upadacitinib","Efficacy","NOT_YET_RECRUITING","2026-01-12",{"date":225,"type":226},"2026-01-21","ACTUAL",{"date":228,"type":212},"2026-03-01",{"date":230,"type":212},"2030-03-30",{"name":5,"class":6},14]